Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2023 Nov 24

PMID 37999131

Authors

Fuat Bicer

Catrina Kure

Anil A Ozluk

Bassel F El-Rayes

Mehmet Akce

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths in the world. More than half of patients with HCC present with advanced stage, and highly active systemic therapies are crucial for improving outcomes. Immune checkpoint inhibitor (ICI)-based therapies have emerged as novel therapy options for advanced HCC. Only one third of patients achieve an objective response with ICI-based therapies due to primary resistance or acquired resistance. The liver tumor microenvironment is naturally immunosuppressive, and specific mutations in cell signaling pathways allow the tumor to evade the immune response. Next, gene sequencing of the tumor tissue or circulating tumor DNA may delineate resistance mechanisms to ICI-based therapy and provide a rationale for novel combination therapies. In this review, we discuss the results of key clinical trials that have led to approval of ICI-based therapy options in advanced HCC and summarize the ongoing clinical trials. We review resistance mechanisms to ICIs and discuss how immunotherapies may be optimized based on the emerging research of tumor biomarkers and genomic alterations.

Citing Articles

TREM2 promotes the formation of a tumor-supportive microenvironment in hepatocellular carcinoma.

Guo H, Wang M, Ni C, Yang C, Fu C, Zhang X J Exp Clin Cancer Res. 2025; 44(1):20.

PMID: 39838454 PMC: 11748316. DOI: 10.1186/s13046-025-03287-w.

Global research trends and frontiers in ferroptosis in hepatocellular carcinoma: a bibliometric and visualization study.

Ning L, Chen D, Han J, Xie G, Sun J Front Oncol. 2024; 14:1474496.

PMID: 39723378 PMC: 11668663. DOI: 10.3389/fonc.2024.1474496.

A Novel Prognostic Nomogram Based on TIGIT and NKG2A Can Predict Relapse-Free Survival of Hepatocellular Carcinoma After Hepatectomy.

Wang J, Cao Y, Tian Y, Dai C, Jin T, Xu F Cancer Med. 2024; 13(22):e70419.

PMID: 39540362 PMC: 11561519. DOI: 10.1002/cam4.70419.

Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges.

Rizzo A, Brunetti O, Brandi G Int J Mol Sci. 2024; 25(20).

PMID: 39456872 PMC: 11507510. DOI: 10.3390/ijms252011091.

New advances in the treatment of intermediate and advanced hepatocellular carcinoma.

Zhonghao J, Fan Y Front Oncol. 2024; 14:1430991.

PMID: 39376988 PMC: 11456399. DOI: 10.3389/fonc.2024.1430991.

References

Pelizzaro F, Farinati F, Trevisani F . Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. Biomedicines. 2023; 11(4). PMC: 10135644. DOI: 10.3390/biomedicines11041020. View

McGlynn K, Petrick J, El-Serag H . Epidemiology of Hepatocellular Carcinoma. Hepatology. 2020; 73 Suppl 1:4-13. PMC: 7577946. DOI: 10.1002/hep.31288. View

Viveiros P, Riaz A, Lewandowski R, Mahalingam D . Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel). 2019; 11(8). PMC: 6721343. DOI: 10.3390/cancers11081085. View

Shetty S, Lalor P, Adams D . Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol. 2018; 15(9):555-567. PMC: 7096836. DOI: 10.1038/s41575-018-0020-y. View

Pinter M, Jain R, Duda D . The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2020; 7(1):113-123. PMC: 8265820. DOI: 10.1001/jamaoncol.2020.3381. View

De Lorenzo S, Tovoli F, Trevisani F . Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2022; 14(19). PMC: 9564277. DOI: 10.3390/cancers14194616. View

Zhu A, Abbas A, Ruiz de Galarreta M, Guan Y, Lu S, Koeppen H . Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022; 28(8):1599-1611. DOI: 10.1038/s41591-022-01868-2. View

Huo J, Wang Y, Fu W, Lu N, Liu Z . The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022; 13:956090. PMC: 9361790. DOI: 10.3389/fimmu.2022.956090. View

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

10.

Zhong C, Li Y, Yang J, Jin S, Chen G, Li D . Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol. 2021; 11:589680. PMC: 8039369. DOI: 10.3389/fonc.2021.589680. View

11.

Lee W, Lee Y, Choi M, Yun K, Won C, Lee M . Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes. J Am Acad Dermatol. 2019; 81(1):219-227. DOI: 10.1016/j.jaad.2019.03.012. View

12.

Lee J, Lee J, Lim Y, Yeon J, Song T, Yu S . Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2018; 68(1):23-32. PMC: 6326973. DOI: 10.1007/s00262-018-2247-4. View

13.

Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C . Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 2013; 134(2):342-51. DOI: 10.1002/ijc.28372. View

14.

He Y, Yu H, Rozeboom L, Rivard C, Ellison K, Dziadziuszko R . LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017; 12(5):814-823. DOI: 10.1016/j.jtho.2017.01.019. View

15.

Du F, Yang L, Liu J, Wang J, Fan L, Duangmano S . The role of mitochondria in the resistance of melanoma to PD-1 inhibitors. J Transl Med. 2023; 21(1):345. PMC: 10207731. DOI: 10.1186/s12967-023-04200-9. View

16.

Yau T, Park J, Finn R, Cheng A, Mathurin P, Edeline J . Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2021; 23(1):77-90. DOI: 10.1016/S1470-2045(21)00604-5. View

17.

Roy A . Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma. J Clin Exp Hepatol. 2022; 12(6):1575-1576. PMC: 9630017. DOI: 10.1016/j.jceh.2022.07.003. View

18.

Liu S, Tang Q, Huang J, Zhan M, Zhao W, Yang X . Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. Aging (Albany NY). 2021; 13(8):11257-11280. PMC: 8109113. DOI: 10.18632/aging.202811. View

19.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

20.

Lu X, Zhou B, Cao M, Shao Q, Pan Y, Zhao T . CTEN Inhibits Tumor Angiogenesis and Growth by Targeting VEGFA Through Down-Regulation of β-Catenin in Breast Cancer. Technol Cancer Res Treat. 2021; 20:15330338211045506. PMC: 8661028. DOI: 10.1177/15330338211045506. View